Background: FGM is less invasive than traditional glucometer. Recent studies show benefits on glycemic control and frequency of hypoglycemia, both in type 1 and type 2 diabetes. Nonetheless, experiences on the impact of this technology in the clinical setting are still scantly reported.

Aim of the Study: To verify impact of FGM on glycemic control in type 1 diabetes subjects (T1DM). Patients and Methods: From January 2017 to December 2018, 397 T1DM subjects (age 43±13 years; diabetes duration 21±13 years; MDI 81%, CSII 19%; BMI 25.4±4.8 Kg/m2; Insulin Requirements (IR) 44±21 U/day; 8 episodes of severe asymptomatic hypoglycemia in the previous 6 months; 3 ketoacidosis; Test strips: 158± 28/month) were started on FGM. A 6-month follow-up (FU) was available for 350 subjects, 204 had a 12-month FU and 39 18-month FU.

Results: Out of 397 subjects, 18 discontinued (patch allergy: 4; inaccuracy: 5; switched to other devices: 3). In 6-month FU patients, HbA1c declined from 58±14 to 56±12 mmol/mol (p<0.00001). The improvement was more apparent in MDI (n=271; from 59±15 to 56±12 mmol/mol, p <0.0001) than in CSII (n=79, 57±11 to 55±10 mmol/mol, p=0.14). In 12-month FU patients (n=204), basal, 6, and 12 month HbA1c was 58±14, 56±12 (p=0.04) and 56±12 mmol/mol (p =0.004) also more apparent with MDI (n=152, 59±14, 57±13 - p=0.05, and 56±12 mmol/mol - p<0.0009) than with CSII (n=52, 56±11, 55±10, 56±9 mmol/mol, p=NS). In 18-month FU subjects (n=35) basal, 6, 12 and 18-month HbA1c were 58±11, 56±10 - p=0.06, 56±9 - p=0.19, 55±9 mmol/mol - p =0.03). In multivariate analysis, HbA1c reduction was not correlated with disease duration, age, and baseline HbA1c.In the whole cohort there was 1 episode of severe asymptomatic hypoglycemia and 2 of ketoacidosis in the CSII group.

Conclusions and comments: In our clinical practice, FGM was associated with small but significant reduction in HbA1c (particularly for patient on MDI) and severe asymptomatic hypoglycemia.


C. Rodia: None. C. Bianchi: None. A. Bertolotto: Speaker's Bureau; Self; Abbott, Lilly Diabetes. R. Giannarelli: None. F. Campi: None. S. Del Prato: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Sanofi, Servier, Takeda Pharmaceutical Company Limited. Board Member; Self; AstraZeneca. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited. M. Aragona: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at